8-KLeadership ChangesExhibits & Filings

Guardant Health, Inc. 8-K Report, Executive Changes (May 8, 2023)

Filed May 8, 2023For Securities:GH

Summary

Guardant Health, Inc. (GH) announced a key executive appointment via an 8-K filing on May 8, 2023, detailing the addition of Ines Dahne-Steuber as Chief Operations Officer (COO) effective May 3, 2023. Ms. Dahne-Steuber brings extensive operational and leadership experience from prominent healthcare companies such as Fresenius Medical Care and Quest Diagnostics, with a strong background in operational excellence and oncology. Her appointment is accompanied by a comprehensive compensation package designed to attract and retain top talent. This includes a base salary of $490,000, a target bonus of 50% of base salary, and significant equity awards valued at approximately $2 million each in restricted stock units (RSUs) and stock options. The equity awards have staggered vesting schedules, with full vesting over four years, aligning her incentives with the company's long-term performance. Additionally, she will receive a $50,000 signing bonus and a relocation allowance of up to $50,000, subject to clawback provisions.

Key Highlights

  • 1Guardant Health appointed Ines Dahne-Steuber as Chief Operations Officer (COO) effective May 3, 2023.
  • 2Ms. Dahne-Steuber has significant prior experience in operational leadership roles at Fresenius Medical Care and Quest Diagnostics, including in oncology and healthcare IT.
  • 3Her compensation package includes an annual base salary of $490,000 and a target bonus of 50% of her base salary.
  • 4She will receive equity awards valued at approximately $2 million in RSUs and $2 million in stock options.
  • 5Equity awards are structured with a four-year vesting period, aligning with long-term company performance.
  • 6Ms. Dahne-Steuber is also entitled to a $50,000 signing bonus and a relocation allowance up to $50,000.
  • 7The company is entering into a standard indemnification agreement with the new COO.

Frequently Asked Questions

The appointment of Ines Dahne-Steuber as Chief Operations Officer is significant as it brings experienced leadership to a critical operational role within Guardant Health. Her background in operational excellence and leadership at major healthcare and diagnostics companies like Fresenius Medical Care and Quest Diagnostics suggests a focus on enhancing the company's operational efficiency, execution, and scaling of its services, which is vital for a growing biotech company.

Ms. Dahne-Steuber's compensation package is robust, including a $490,000 base salary, a 50% target bonus, and substantial equity awards ($2 million each in RSUs and stock options) with a four-year vesting schedule. This level of compensation, particularly the significant equity component, indicates the company's commitment to attracting high-caliber executive talent and aligning her incentives with long-term shareholder value creation. The signing bonus and relocation assistance further underscore the company's efforts to secure her commitment.

The signing bonus and relocation allowance are subject to clawback provisions if Ms. Dahne-Steuber voluntarily terminates her employment within the first 12 months. This is a standard practice to ensure commitment from the executive. Additionally, the equity awards are subject to continued service and have specific vesting schedules, meaning she must remain employed by Guardant Health for a specified period to realize the full value of these awards.